HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lamhamedi-Cherradi, S.-E. Articles by Chen, Y. H. Search for Related Content PubMed PubMed Citation Articles by Lamhamedi-Cherradi, S.-E. Articles by Chen, Y. H. Social Bookmarking                What's this?

Critical Roles of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand in Type 1 Diabetes

¹ Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
² Department of Microbiology and Immunology, University of North Carolina–Chapel Hill, Chapel Hill, North Carolina

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis of tumor cells but not most normal cells. Its roles in normal nontransformed tissues are not clear. To explore the potential roles of TRAIL in type 1 diabetes, we examined the consequences of TRAIL blockade or TRAIL deficiency in two animal models of autoimmune diabetes. In the first model, NOD mice received an injection of a soluble TRAIL receptor to block TRAIL function. This significantly accelerated the diabetes and increased the degree of autoimmune inflammation in both pancreatic islets and salivary glands. The GAD65-specific immune responses were also significantly enhanced in animals that received the soluble TRAIL receptor. In the second model, we treated normal and TRAIL-deficient C57BL/6 mice with multiple low-dose streptozotocin to induce diabetes. We found that both the incidence and the degree of islet inflammation were significantly enhanced in TRAIL-deficient animals. On the basis of these observations, we conclude that TRAIL deficiency accelerates autoimmune diabetes and enhances autoimmune responses.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Goldberg, M. Parolini, B. Y. Chin, E. Czismadia, L. E. Otterbein, F. H. Bach, and H. Wang Toll-like receptor 4 suppression leads to islet allograft survival FASEB J, September 1, 2007; 21(11): 2840 - 2848. [Abstract] [Full Text] [PDF]

				V. Rus, V. Nguyen, R. Puliaev, I. Puliaeva, V. Zernetkina, I. Luzina, J. C. Papadimitriou, and C. S. Via T Cell TRAIL Promotes Murine Lupus by Sustaining Effector CD4 Th Cell Numbers and by Inhibiting CD8 CTL Activity J. Immunol., March 15, 2007; 178(6): 3962 - 3972. [Abstract] [Full Text] [PDF]

				M. A. Cassatella On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils J. Leukoc. Biol., June 1, 2006; 79(6): 1140 - 1149. [Abstract] [Full Text] [PDF]

				J. J. Lum, G. Bren, R. McClure, and A. D. Badley Elimination of Senescent Neutrophils by TNF-Related Apotosis-Inducing Ligand J. Immunol., July 15, 2005; 175(2): 1232 - 1238. [Abstract] [Full Text] [PDF]

				M. Huang, K. Matthews, T. J. Siahaan, and C. G. Kevil {alpha}L-Integrin I domain cyclic peptide antagonist selectively inhibits T cell adhesion to pancreatic islet microvascular endothelium Am J Physiol Gastrointest Liver Physiol, January 1, 2005; 288(1): G67 - G73. [Abstract] [Full Text] [PDF]

				S.-J. Zheng, J. Jiang, H. Shen, and Y. H. Chen Reduced Apoptosis and Ameliorated Listeriosis in TRAIL-Null Mice J. Immunol., November 1, 2004; 173(9): 5652 - 5658. [Abstract] [Full Text] [PDF]